Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: June 25, 2008
Last updated: August 11, 2009
Last verified: November 2008

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the steady-state safety, toleration and pharmacokinetics of multiple oral dose administration of CP-945598. Results will be used to estimate the pharmacokinetic characteristics in NASH patients and underwrite the safety of this compound prior to any further studies in NASH patients.

Condition Intervention Phase
Non-Alcoholic Steatohepatitis(NASH)
Drug: Active treatment
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Basic Science
Official Title: A Multiple Dose, Randomized, Double-Blind (3rd Party Open), Placebo-Controlled Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of CP-945598 In Subjects With Nonalcoholic Steatohepatitis (NASH)

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Urine 6-β-hydroxycortisol:cortisol ratio [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  • Adverse event monitoring, physical examinations, sitting vital sign measurements (blood pressure and pulse rate), 12-lead ECGs, laboratory safety assessments. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • PK for CP-945598 and its primary circulating metabolite [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Breath ID® tests (methacetin and octanoate) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Soluble and exploratory biomarkers [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Enrollment: 9
Study Start Date: July 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CP-945598 20 mg Drug: Active treatment
20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
Placebo Comparator: Placebo Drug: Placebo
Placebo as two tablets once daily for three weeks


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body Mass Index (BMI) of 25 to 40 kg/m2
  • Subjects with biopsy evidence of NASH in the 2 years prior to the screening visit.

Hemoglobin ≥11 g/dL, platelet count ≥100,000 cells/mm3, neutrophil count ≥1,500cells/mm3.

Exclusion Criteria:

  • Other forms than NASH liver disease.
  • Decompensated or severe liver disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00706537

United States, California
Pfizer Investigational Site
Anaheim, California, United States, 92801
Pfizer Investigational Site
Anaheim, California, United States, 92804
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00706537     History of Changes
Other Study ID Numbers: A5351053
Study First Received: June 25, 2008
Last Updated: August 11, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Pharmacokinetic safety NASH patients

Additional relevant MeSH terms:
Fatty Liver
Digestive System Diseases
Liver Diseases processed this record on November 24, 2014